Lundbeck loses €150m pay-for-delay appeal

Lundbeck has lost an appeal to the Court of Justice of the European Union (CJEU) to waive €150 million ($176 million) in fines levied against itself and a group of five generics manufacturers over ‘pay-for-delay’ deals for its antidepressant generics.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Generics

Why the ‘first penguin’ of pay for delay has not come in Japan: anatomy of a Japan paradox

27 May 2022 Why does Japan have no reverse payments culture? Takanori Abe of Abe & Partners unpicks a complex issue.

Big Pharma

AG advises CJEU to uphold €94 million pay-for-delay fine

5 June 2020 The advocate general has recommended that the Court of Justice of the European Union uphold an almost €94 million fine imposed on Lundbeck for its pay-for-delay scheme.

Big Pharma

EU General Court backs Lundbeck fine in pay-for-delay case

12 September 2016 The EU General Court has backed the European Commission’s decision to fine pharma company Lundbeck and a number of generic producers.

More features

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

Lundbeck loses €150m pay-for-delay appeal

More on this story

Editor's picks

Editor's picks

More features